HEPATIC FFA DELIVERY IN NIDDM/HYPERLIPIDEMIA

本研究的目的是确定患有和不患有非胰岛素依赖型糖尿病的肥胖和非肥胖个体的肝脏是否暴露于血液中过量的脂肪。研究结果表明，肥胖患者肝脏游离脂肪酸排泄量增加，但内脏脂肪主要在肥胖女性肝脏游离脂肪酸排泄量增加中起重要作用。我们发现，在女性中，内脏脂肪量与内脏脂肪分解向肝脏输送的FFA百分比呈正相关，但在男性中没有发现这种关系。本研究的阳性结果为DK 40484的竞争性更新提供了重要的初步数据。我们相信我们已经完成了本研究的志愿者招募。该研究的减肥部分，包括一个随机、安慰剂对照、盲法分配的超重志愿者芬氟拉明/芬特明，由于瓣膜性心脏病而停止。所有志愿者已停止服药并接受超声心动图检查。对研究结果进行了分析。在完成动物研究以验证我们用于估计肝脏FFA递送的模型之前，研究结果将提交发表。

The purpose of this study is to determine whether the liver is exposed to excessive amounts of fat present in the bloodstream in obese and non-obese individuals with and without noninsulin-dependent diabetes mellitus. The results of the study indicate that hepatic FFA delivery is increased in obesity, but that visceral fat plays a significant role in increasing hepatic FFA delivery primarily in obese women. We found a positive correlation between visceral fat mass and the percentage of FFA delivered to the liver from visceral lipolysis in women, but did not find this relationship in men. The positive results from this study were important preliminary data for the competing renewal for DK 40484. We believe we have completed volunteer recruitment for this study. The weight loss portion of this study that included a randomized, placebo-controlled, blinded assignment of overweight volunteers to fenfluramine/phentermine was discontinued because of valvular heart disease. All volunteers have been removed from the medication and are being followed with echocardiography. Results of the studies have been analyzed. Pending the completion of animal studies to validate the model we used to estimate hepatic FFA delivery, the results of the studies will be submitted for publication.